B
Biotech Unveiled
Course Progress
0%
Chapter 8

Confronting the Threat to US Biomedical Innovation

Chapter 8 Overview
The Drug Pricing Maze Why Price Controls are Problematic Drugs Going Generic IS the Built in Price Control Things that Don't Work Borrowing From Other Countries International Reference Pricing Drug Reimportation Seizing IP: March-in Rights Seizing IP: TRIPS Waivers Check Your Understanding Quiz 8.1 Things that Might Work Lowering OOPs and the Good Parts of the IRA Guaranteed Contracts/Forward Contracts Getting the International Community On Board Forward contracts for Antibiotics: The Pasteur Act Generalized Cost Effectiveness Analysis (GCEA) Check Your Understanding Quiz 8.2 The Best 8% of Our Healthcare Dollar Chapter 8 Summary OPTIONAL] Additional Resources The Beginning of the End: Wrapping up our course Looking Back First Responder Survey Sign Up to be a First Responder
Engagement: low
0h 01m 01s

Chapter 8 Overview

In this Chapter, we’ll examine:

  1. Why Price Controls are Problematic

  2. Drugs Going Generic Is a Built in Price Control. (Unless they don’t go generic.)

  3. The impact of the Inflation Reduction Act

  4. Borrowing from Other Countries

  5. Ignoring Patents

    • TRIPS Waivers, March-In Rights
  6. Guaranteed Contracts

  7. The X-Prize Model and PASTEUR

  8. Ex-US Patent Enforcement/Lack Thereof

  9. Value and GCEA

< Previous And one more thing...
Next The Drug Pricing Maze

© 2026 RA Capital Management. All rights reserved.

A Modern, Interactive Learning Experience